Premium
Cost of treating recurrent respiratory papillomavirus in commercially insured and medicaid patients
Author(s) -
Tam Samantha,
Wu ChiFang,
Peng HoLan,
Dahlstrom Kristina R.,
Sturgis Erich M.,
Lairson David R.
Publication year - 2020
Publication title -
the laryngoscope
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.181
H-Index - 148
eISSN - 1531-4995
pISSN - 0023-852X
DOI - 10.1002/lary.28139
Subject(s) - medicine , recurrent respiratory papillomatosis , medicaid , population , juvenile , pediatrics , age of onset , disease , surgery , health care , environmental health , biology , economics , genetics , economic growth
Objectives The study objective was to estimate the first 2 years’ direct costs of treating new cases of juvenile‐onset and adult‐onset recurrent respiratory papillomatosis (RRP) and determine the predictors of treatment costs. Methods Cases were patients diagnosed with RRP in commercial insurance claims in 2011–2014 and Texas Medicaid in 2008–2012 for treatment of RRP. Controls were patients without a diagnosis of HPV‐related cancer or RRP, matched with cases by age, sex, geographic area, date of diagnosis of RRP, and propensity score. Total health care costs in the first 2 years after diagnosis were obtained from cases and matched controls. A generalized linear model was created to identify predictors of monthly costs. Results In commercially insured patients, a total of 122 cases of juvenile‐onset (<18 years old) and 1824 cases of adult‐onset (≥18 years old) RRP were identified. The mean first 2 years’ cost difference between cases and controls was $58,733 for juvenile‐onset disease and $11,185 for adult‐onset disease after model adjustments. In the Texas Medicaid population, 73 cases of juvenile‐onset and 96 cases of adult‐onset RRP were identified. The mean first 2 years’ cost difference between cases and controls was $76,115 for juvenile‐onset disease and $4,633 for adult‐onset disease after model adjustments. Conclusion The first 2 years’ medical costs difference of juvenile‐onset and adult‐onset RRP among commercially insured and Medicaid population were approximately $60,000 to $70,000 and $5,000 to $11,000, respectively, and should be considered in HPV vaccination promotion investment decisions. Level of Evidence N/A Laryngoscope , 130:1186–1194, 2020